The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer
Open accessAbstract
IMPORTANCE: A critical decision in the management of metastatic castration-resistant prostate cancer (mCRPC) is when to administer an androgen receptor signaling (ARS) inhibitor or a taxane. OBJECTIVE: To determine if pretherapy nuclear androgen-receptor splice variant 7 (AR-V7) protein expression and localization on circulating tumor cells (CTCs) is a treatment-specific marker for response and outcomes between ARS inhibitors and taxanes. DESIGN, SETTING, AND PARTICIPANTS: For this cross-sectional cohort study at Memorial Sloan Kettering Cancer Center, 265 men with progressive mCRPC undergoing a change in treatment were considered; 86 were excluded because they were not initiating ARS or taxane therapy; and 18 were excluded for processing time constraints, leaving 161 patients for analysis. Between December 2012 and March 2015, blood was collected and processed from patients with progressive mCRPC immediately prior to new line of systemic therapy. Patients were followed up to 3 years. MAIN OUTCOMES AND MEASURES: Prostate-specific antigen (PSA) response, time receiving therapy, radiographic progression-free survival (rPFS), and overall survival (OS). RESULTS: Overall, of 193 prospectively collected blood samples from 161 men with mCRPC, 191 were evaluable (128 pre-ARS inhibitor and 63 pretaxane). AR-V7-positive CTCs were found in 34 samples (18%), including 3% of first-line, 18% of second-line, and 31% of third- or greater line samples. Patients whose samples had AR-V7-positive CTCs before ARS inhibition had resistant posttherapy PSA changes (PTPC), shorter rPFS, shorter time on therapy, and shorter OS than those without AR-V7-positive CTCs. Overall, resistant PTPC were seen in 65 of 112 samples (58%) without detectable AR-V7-positive CTCs prior to ARS inhibition. There were statistically significant differences in OS but not in PTPC, time on therapy, or rPFS for patients with or without pretherapy AR-V7-positive CTCs treated with a taxane. A multivariable model adjusting for baseline factors associated with survival showed superior OS with taxanes relative to ARS inhibitors when AR-V7-positive CTCs were detected pretherapy (hazard ratio, 0.24; 95% CI, 0.10-0.57; P = .035). CONCLUSIONS AND RELEVANCE: The results validate CTC nuclear expression of AR-V7 protein in men with mCRPC as a treatment-specific biomarker that is associated with superior survival on taxane therapy over ARS-directed therapy in a clinical practice setting. Continued examination of this biomarker in prospective studies will further aid clinical utility.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Antonarakis, E. S., Lu, C., Wang, H., Luber, B., Nakazawa, M., Roeser, J. C., Chen, Y., Mohammad, T. A., Chen, Y., Fedor, H. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315815 · Cited by 2,710
The Robust Inference for the Cox Proportional Hazards Model
Lin, D. Y., & Wei, L. J. (1989) · Journal of the American Statistical Association · doi:10.1080/01621459.1989.10478874 · Cited by 2,695
Scher, H. I., Halabi, S., Tannock, I., Morris, M., Sternberg, C. N., Carducci, M. A., Eisenberger, M. A., Higano, C., Bubley, G. J., Dreicer, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.4487 · Cited by 2,241
Self-citationScher, H. I., Morris, M. J., Stadler, W. M., Higano, C., Basch, E., Fizazi, K., Antonarakis, E. S., Beer, T. M., Carducci, M. A., Chi, K. N., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.2702 · Cited by 1,654
Self-citationGuo, Z., Yang, X., Sun, F., Jiang, R., Linn, D. E., Chen, H., Chen, H., Kong, X., Melamed, J., Tepper, C. G., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3795 · Cited by 880
Li, Y., Chan, S. C., Brand, L. J., Hwang, T. H., Silverstein, K. A. T., & Dehm, S. M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3630 · Cited by 680
Watson, P. A., Chen, Y. F., Balbas, M. D., Wongvipat, J., Socci, N. D., Viale, A., Kim, K., & Sawyers, C. L. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012443107 · Cited by 639
Molecular analysis of circulating tumour cells—biology and biomarkers
Krebs, M. G., Metcalf, R. L., Carter, L., Brady, G., Blackhall, F. H., & Dive, C. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.253 · Cited by 622
Antonarakis, E. S., Lu, C., Luber, B., Wang, H., Chen, Y., Nakazawa, M., Nadal, R., Paller, C. J., Denmeade, S. R., Carducci, M. A., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.1341 · Cited by 618
Biology, detection, and clinical implications of circulating tumor cells
Joosse, S. A., Gorges, T. M., & Pantel, K. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201303698 · Cited by 528
Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers
Marrinucci, D., Bethel, K., Kolatkar, A., Luttgen, M. S., Malchiodi, M., Baehring, F., Voigt, K., Lazar, D., Nieva, J., Bazhenova, L., et al. (2012) · Physical Biology · doi:10.1088/1478-3975/9/1/016003 · Cited by 302
Self-citationSchrader, A. J., Boegemann, M., Ohlmann, C.-H., Schnoeller, T. J., Krabbe, L.-M., Hajili, T., Jentzmik, F., Stoeckle, M., Schrader, M., Herrmann, E., et al. (2014) · European Urology · doi:10.1016/j.eururo.2013.06.042 · Cited by 284
Efstathiou, E., Titus, M., Wen, S., Hoang, A., Karlou, M., Ashe, R., Tu, S. M., Aparicio, A., Troncoso, P., Mohler, J., et al. (2015) · European Urology · doi:10.1016/j.eururo.2014.05.005 · Cited by 248
Onstenk, W., Sieuwerts, A. M., Kraan, J., Van, M., Nieuweboer, A. J. M., Mathijssen, R. H. J., Hamberg, P., Meulenbeld, H. J., De Laere, B., Dirix, L. Y., et al. (2015) · European Urology · doi:10.1016/j.eururo.2015.07.007 · Cited by 237
Circulating Tumor Cells: A Multifunctional Biomarker
Yap, T. A., Lorente, D., Omlin, A., Olmos, D., & de Bono, J. S. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2664 · Cited by 206
Serial blood-based analysis of AR-V7 in men with advanced prostate cancer
Nakazawa, M., Lu, C., Chen, Y., Paller, C. J., Carducci, M. A., Eisenberger, M. A., Luo, J., & Antonarakis, E. S. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv282 · Cited by 178
Ware, K. E., García-Blanco, M. A., Armstrong, A. J., & Dehm, S. M. (2014) · Endocrine Related Cancer · doi:10.1530/erc-13-0470 · Cited by 166
Qu, Y., Dai, B., Ye, D., Kong, Y., Chang, K., Jia, Z., Yang, X., Zhang, H., Zhu, Y., & Shi, G. (2015) · Scientific Reports · doi:10.1038/srep07654 · Cited by 161
Templeton, A. J., Vera-Badillo, F., Wang, L., Attalla, M., Gouveia, P. D., Leibowitz‐Amit, R., Knox, J. J., Moore, M. J., Sridhar, S. S., Joshua, A. M., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt397 · Cited by 137
Werner, S. L., Graf, R. P., Landers, M. A., Valenta, D. T., Schroeder, M. J., Greene, S. B., Bales, N., Dittamore, R. V., & Marrinucci, D. C. (2015) · Journal of Circulating Biomarkers · doi:10.5772/60725 · Cited by 133
Self-citationSun, F., Chen, H.-G., Li, W., Yang, X., Wang, X., Jiang, R., Guo, Z., Chen, H., Huang, J., Borowsky, A. D., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.492140 · Cited by 96
Validation and clinical utility of prostate cancer biomarkers
Scher, H. I., Morris, M. J., Larson, S. M., & Heller, G. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.30 · Cited by 96
Self-citationPunnoose, E. A., Ferraldeschi, R., Szafer‐Glusman, E., Tucker, E., Mohan, S., Flohr, P., Riisnaes, R., Miranda, S., Figueiredo, I., Rodrigues, D. N., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.332 · Cited by 95
Self-citationPopulation-based study on use of chemotherapy in men with castration resistant prostate cancer
Lissbrant, I. F., Garmo, H., Widmark, A., & Stattin, P. (2013) · Acta Oncologica · doi:10.3109/0284186x.2013.770164 · Cited by 56
The Emerging Role of Circulating Tumor Cell Detection in Genitourinary Cancer
Small, A., Gong, Y., Oh, W. K., Hall, S. J., van Rijn, C. J. M., & Galsky, M. D. (2012) · The Journal of Urology · doi:10.1016/j.juro.2012.02.2558 · Cited by 51
Pond, G. R., Armstrong, A. J., Wood, B. A., Brookes, M., Leopold, L. H., Berry, W. R., de Wit, R., Eisenberger, M. A., Tannock, I. F., & Sonpavde, G. (2011) · European Urology · doi:10.1016/j.eururo.2011.06.034 · Cited by 39
Clinical Relevance of Androgen Receptor Splice Variants in Castration-Resistant Prostate Cancer
Maughan, B. L., & Antonarakis, E. S. (2015) · Current Treatment Options in Oncology · doi:10.1007/s11864-015-0375-z · Cited by 29
Antonarakis, E. S. (2014) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2015.999044 · Cited by 25
Cited by
Liquid biopsy enters the clinic — implementation issues and future challenges
Ignatiadis, M., Sledge, G. W., & Jeffrey, S. S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00457-x · Cited by 1,191
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
Gillessen, S., Attard, G., Beer, T. M., Beltran, H., Bossi, A., Bristow, R., Carver, B., Castellano, D., Chung, B. H., Clarke, N., et al. (2018) · European Urology · doi:10.1016/j.eururo.2017.06.002 · Cited by 642
Self-citationSartor, O., & de Bono, J. S. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1701695 · Cited by 546
NCCN Guidelines Insights: Prostate Cancer, Version 1.2021: Featured Updates to the NCCN Guidelines
Schaeffer, E., Srinivas, S., Antonarakis, E. S., Armstrong, A. J., Bekelman, J. E., Cheng, H., D’Amico, A. V., Davis, B. J., Desai, N., Dorff, T., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0008 · Cited by 525
Metadata
- Authors
- Scher, H. I., Lu, D., Schreiber, N. A., Louw, J., Graf, R. P., Vargas, H. A., Johnson, A., Jendrisak, A., Bambury, R., Danila, D., McLaughlin, B., Wahl, J., Greene, S. B., Heller, G., Marrinucci, D., Fleisher, M., & Dittamore, R.
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2016-11-01
- Volume
- 2
- Issue
- 11
- Pages
- 1441
- ISSN
- 2374-2437 (ISSN-L)
- OpenAlex
- W2419426348
- Cited by
- 641
- References
- 28
- FWCI
- 85.80
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.